Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Palvella Therapeutics ( (PVLA) ).
On February 25, 2026, Palvella Therapeutics, Inc. entered into an underwriting agreement to issue and sell 1,600,000 shares of common stock at $125.00 per share, with underwriters granted a 30‑day option to purchase up to an additional 240,000 shares. The company expects net proceeds of approximately $187.3 million, with the offering, made via an SEC‑filed prospectus supplement under an effective shelf registration, scheduled to close on or about February 27, 2026, subject to customary conditions.
All of the shares in the offering are being sold by Palvella, and the company has provided customary representations, warranties, covenants and indemnification to the underwriters. Palvella plans to use the proceeds, together with existing cash and marketable securities, to advance development of its QTORIN rapamycin and QTORIN pitavastatin programs and to fund working capital and general corporate purposes, including research and development, potentially strengthening its balance sheet and supporting continued pipeline investment.
The most recent analyst rating on (PVLA) stock is a Buy with a $210.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
The score is held down primarily by weak financial performance (no current revenue, ongoing losses, and persistent cash burn) and bearish technical signals. Offsetting this, corporate events are notably positive with encouraging Phase 2 data and clear near-term clinical/regulatory catalysts, but this does not fully overcome the current fundamentals and trend.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for serious, rare dermatologic and other diseases. Its pipeline includes topical formulations such as QTORIN rapamycin and QTORIN pitavastatin, reflecting a market focus on targeted, late-stage clinical programs aimed at underserved patient populations.
Average Trading Volume: 292,050
Technical Sentiment Signal: Buy
Current Market Cap: $1.43B
For detailed information about PVLA stock, go to TipRanks’ Stock Analysis page.